FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2798102020> ?p ?o ?g. }

• W2798102020 endingPage "3385" @default.
• W2798102020 startingPage "3377" @default.
• W2798102020 abstract "Abstract Purpose: BRAF and MEK inhibitors (BRAF/MEKi) favor melanoma-infiltrating lymphocytes, providing the rationale for current combinatorial trials with anti–PD-1 antibody. A portion of melanoma cells may express PD-1, and anti–PD-1 antibody could have a direct antitumor effect. Here, we explore whether BRAF/MEKi modulate rates of PD-1+ melanoma cells, supporting an additional—lymphocyte-independent—basis for their therapeutic combination with anti–PD-1 antibody. Experimental Design: With data mining and flow cytometry, we assessed PD-1, PD-L1/2 expression on melanoma cell lines (CCLE, N = 61; validation cell lines, N = 7) and melanoma tumors (TCGA, N = 214). We explored in vitro how BRAF/MEKi affect rates of PD-1+, PD-L1/2+ melanoma cells, and characterized the proliferative and putative stemness features of PD-1+ melanoma cells. We tested the functional lymphocyte-independent effect of anti–PD-1 antibody alone and in combination with BRAF/MEKi in vitro and in an in vivo immunodeficient murine model. Results: PD-1 is consistently expressed on a small subset of melanoma cells, but PD-1+ cells increase to relevant rates during BRAF/MEKi treatment [7.3% (5.6–14.2) vs. 1.5% (0.7–3.2), P = 0.0156; N = 7], together with PD-L2+ melanoma cells [8.5% (0.0–63.0) vs. 1.5% (0.2–43.3), P = 0.0312; N = 7]. PD-1+ cells proliferate less than PD-1− cells (avg. 65% less; t = 7 days) and are preferentially endowed with stemness features. In vivo, the direct anti-melanoma activity of PD-1 blockage as monotherapy was negligible, but its association with BRAF/MEKi significantly delayed the development of drug resistance and tumor relapse. Conclusions: BRAF/MEKi increase the rates of PD-1+ melanoma cells that may sustain tumor relapse, providing a lymphocyte-independent rationale to explore combinatory strategies with anti–PD-1 antibody. Clin Cancer Res; 24(14); 3377–85. ©2018 AACR." @default.
• W2798102020 created "2018-04-24" @default.
• W2798102020 creator A5017731904 @default.
• W2798102020 creator A5031267534 @default.
• W2798102020 creator A5032966282 @default.
• W2798102020 creator A5040398579 @default.
• W2798102020 creator A5041240875 @default.
• W2798102020 creator A5042196465 @default.
• W2798102020 creator A5044726648 @default.
• W2798102020 creator A5051114812 @default.
• W2798102020 creator A5056702454 @default.
• W2798102020 creator A5059509038 @default.
• W2798102020 creator A5066790760 @default.
• W2798102020 creator A5068859041 @default.
• W2798102020 creator A5072883486 @default.
• W2798102020 creator A5079227239 @default.
• W2798102020 creator A5083160716 @default.
• W2798102020 creator A5085680955 @default.
• W2798102020 creator A5086890383 @default.
• W2798102020 creator A5088987115 @default.
• W2798102020 date "2018-07-15" @default.
• W2798102020 modified "2023-10-17" @default.
• W2798102020 title "BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody" @default.
• W2798102020 cites W1566969252 @default.
• W2798102020 cites W1758894002 @default.
• W2798102020 cites W1834835434 @default.
• W2798102020 cites W1994548581 @default.
• W2798102020 cites W2018167187 @default.
• W2798102020 cites W2031134972 @default.
• W2798102020 cites W2066717075 @default.
• W2798102020 cites W2068900347 @default.
• W2798102020 cites W2099044540 @default.
• W2798102020 cites W2102265655 @default.
• W2798102020 cites W2103675014 @default.
• W2798102020 cites W2116978375 @default.
• W2798102020 cites W2124185479 @default.
• W2798102020 cites W2127437403 @default.
• W2798102020 cites W2146774792 @default.
• W2798102020 cites W2154841567 @default.
• W2798102020 cites W2155464214 @default.
• W2798102020 cites W2166952326 @default.
• W2798102020 cites W2254594392 @default.
• W2798102020 cites W2546646563 @default.
• W2798102020 cites W2594529508 @default.
• W2798102020 doi "https://doi.org/10.1158/1078-0432.ccr-17-1914" @default.
• W2798102020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29650750" @default.
• W2798102020 hasPublicationYear "2018" @default.
• W2798102020 type Work @default.
• W2798102020 sameAs 2798102020 @default.
• W2798102020 citedByCount "27" @default.
• W2798102020 countsByYear W27981020202018 @default.
• W2798102020 countsByYear W27981020202019 @default.
• W2798102020 countsByYear W27981020202020 @default.
• W2798102020 countsByYear W27981020202021 @default.
• W2798102020 countsByYear W27981020202022 @default.
• W2798102020 countsByYear W27981020202023 @default.
• W2798102020 crossrefType "journal-article" @default.
• W2798102020 hasAuthorship W2798102020A5017731904 @default.
• W2798102020 hasAuthorship W2798102020A5031267534 @default.
• W2798102020 hasAuthorship W2798102020A5032966282 @default.
• W2798102020 hasAuthorship W2798102020A5040398579 @default.
• W2798102020 hasAuthorship W2798102020A5041240875 @default.
• W2798102020 hasAuthorship W2798102020A5042196465 @default.
• W2798102020 hasAuthorship W2798102020A5044726648 @default.
• W2798102020 hasAuthorship W2798102020A5051114812 @default.
• W2798102020 hasAuthorship W2798102020A5056702454 @default.
• W2798102020 hasAuthorship W2798102020A5059509038 @default.
• W2798102020 hasAuthorship W2798102020A5066790760 @default.
• W2798102020 hasAuthorship W2798102020A5068859041 @default.
• W2798102020 hasAuthorship W2798102020A5072883486 @default.
• W2798102020 hasAuthorship W2798102020A5079227239 @default.
• W2798102020 hasAuthorship W2798102020A5083160716 @default.
• W2798102020 hasAuthorship W2798102020A5085680955 @default.
• W2798102020 hasAuthorship W2798102020A5086890383 @default.
• W2798102020 hasAuthorship W2798102020A5088987115 @default.
• W2798102020 hasBestOaLocation W27981020201 @default.
• W2798102020 hasConcept C150903083 @default.
• W2798102020 hasConcept C159654299 @default.
• W2798102020 hasConcept C202751555 @default.
• W2798102020 hasConcept C203014093 @default.
• W2798102020 hasConcept C207001950 @default.
• W2798102020 hasConcept C2777658100 @default.
• W2798102020 hasConcept C2777761686 @default.
• W2798102020 hasConcept C502942594 @default.
• W2798102020 hasConcept C54355233 @default.
• W2798102020 hasConcept C553184892 @default.
• W2798102020 hasConcept C55493867 @default.
• W2798102020 hasConcept C71924100 @default.
• W2798102020 hasConcept C81885089 @default.
• W2798102020 hasConcept C86803240 @default.
• W2798102020 hasConceptScore W2798102020C150903083 @default.
• W2798102020 hasConceptScore W2798102020C159654299 @default.
• W2798102020 hasConceptScore W2798102020C202751555 @default.
• W2798102020 hasConceptScore W2798102020C203014093 @default.
• W2798102020 hasConceptScore W2798102020C207001950 @default.
• W2798102020 hasConceptScore W2798102020C2777658100 @default.
• W2798102020 hasConceptScore W2798102020C2777761686 @default.
• W2798102020 hasConceptScore W2798102020C502942594 @default.

• next